22 Jun 2021
The Lancet Respiratory Medicine: Savolitinib in Chinese NSCLC patients harbouring MET exon 14 skipping alterations
Upcoming Investor Events
Learn More
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
European Lung Cancer Congress 2022
Final OS results and subgroup analysis of savolitinib Phase II study in METex14+ NSCLC
Learn More
Latest News
26 May 2023Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority ReviewRead more 26 May 2023HUTCHMED Highlights Presentations at the 2023 ASCO Annual MeetingRead more 18 Apr 2023HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric CancerRead more
12 Apr 2023HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023Read more 11 Apr 20232022 Annual Report and Notice of Annual General MeetingRead more 4 Apr 2023HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA ConsultationsRead more 31 Mar 2023HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP
THE GROUP
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
